

CYTOKINETICS CONTEMPORARY FORUM

The Trajectory of Worsening Heart Failure and Considerations for Outcomes and Cost of Care

LIVESTREAM AND ON DEMAND | BREAKFAST WILL BE SERVED*

AGENDA

- 6:45 AM- 6:50 AM** **Welcome and Introduction**
Nihar R. Desai
-
- 6:50 AM- 7:05 AM** **The Impact of Healthcare Disparities in Patients With Worsening Heart Failure**
Alanna Morris
-
- 7:05 AM- 7:20 AM** **In-hospital Initiation of Quadruple Medical Therapy for HFrEF**
Stephen J. Greene
-
- 7:20 AM- 7:35 AM** **Key Considerations in Transitions-of-Care for Symptomatic Chronic HFrEF With Worsening Signs and Symptoms**
Anuradha Lala-Trindade
-
- 7:35 AM- 7:45 AM** **Q&A Session and Closing Remarks**
Nihar R. Desai



**SATURDAY,
OCTOBER 1**



**6:45 AM-
7:45 AM ET**



**GAYLORD
NATIONAL
HARBOR
Potomac C**

FACULTY



Nihar R. Desai
MD, MPH

Associate Professor of Medicine and Vice Chief of Section of Cardiovascular Medicine, Yale University School of Medicine; Investigator, Center for Outcomes Research and Evaluation



Anuradha Lala-Trindade
MD

Associate Professor, Icahn School of Medicine at Mount Sinai; Program Director AHFC Fellowship; Deputy Editor, *Journal of Cardiac Failure*; The Zena and Michael A. Wiener Cardiovascular Institute Department of Health Population Science and Statistics



Stephen J. Greene
MD, FACC

Assistant Professor, Division of Cardiology, Advanced Heart Failure & Transplantation, Duke University Medical Center; Duke Clinical Research Institute



Alanna Morris
MD, MSc, FHFA, FACC, FAHA

Associate Professor of Medicine, Director of Heart Failure Research, Associate Fellowship Director, Clinical Investigator Track, Advanced Heart Failure and Transplant/LVAD Emory Clinical Cardiovascular Research Institute

This Industry Contemporary Forum is not part of the scientific program as planned by the HFSA Program Committee. This event is neither sponsored nor endorsed by HFSA. This event does not qualify for continuing education credits. Faculty disclosures will be provided at the presentation.

*Cytokinetics adheres to the PhRMA Code and other industry standards. Meals may be reportable transfers of value for applicable healthcare professionals under federal and state transparency reporting requirements.

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining.

CYTOKINETICS® and the CYTOKINETICS and C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.

©2022 CYTOKINETICS, All Rights Reserved. US-KNH-00119 08/2022



Cytokinetics